Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 3/20 | 0.83 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.83 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.81 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MMP1 | P03956 | 4/20 | 0.69 |
| ▸ | MMP2 | P08253 | 4/20 | 0.69 |
| ▸ | MMP9 | P14780 | 4/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.66 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294402 | 1.00 | TRPM2 (0.83) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2778922 | 0.92 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2778920 | 0.92 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL29401064 | 0.92 | TRPM2 (0.81) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL28809051 | 0.91 | TRPM2 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL28809046 | 0.91 | TRPM2 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2780698 | 0.90 | TRPA1 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2780806 | 0.90 | TRPA1 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2781340 | 0.90 | MEN1 (0.78) | TRPM2LTB4RTRPA1TRPM8MEN1 | |
| SCHEMBL2779999 | 0.90 | TRPA1 (1.00) | TRPM2LTB4RTRPA1TRPM8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107643344-A | Utilize high performance liquid chromatography fluoroscopic examination（HPLC‑FLD）Method analysis measure oat alkaloid | 北京工商大学 | 2018-01-30 | — | — | CN | claimed |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | claimed |
| EP-2185150-B1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-03-14 | — | — | EP | claimed |
| US-20110112187-A1 | Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions | SYGNIS BIOSCIENCE GMBH & CO. KG. (DE) | 2011-05-12 | — | — | US | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | claimed |
| EP-2185150-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | claimed |
| EP-2030617-A1 | Use of tranilast and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | claimed |
| WO-2009024543-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | claimed |
| WO-2006117602-A2 | USE OF AMIDE DERIVATIVES AS TASTE-MODIFYING AGENTS, FLAVOURING COMPOSITIONS AND PRODUCTS CONTAINING THEM | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2006-11-09 | — | — | WO | claimed |
| US-4623724-A | Method for the production of nuclear substituted cinnamoylanthranilic acid salts | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-11-18 | — | — | US | claimed |
| US-4587356-A | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-05-06 | — | — | US | claimed |
| EP-0074725-B1 | A METHOD FOR THE PRODUCTION OF NUCLEAR SUBSTITUTED CINNAMOYLANTHRANILIC ACID DERIVATIVES AND INTERMEDIATES THEREOF | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-12-27 | — | — | EP | claimed |
| US-4486597-A | Method for the production of nuclear substituted cinnamoylanthranilic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-12-04 | — | — | US | claimed |
| EP-0074725-A1 | A method for the production of nuclear substituted cinnamoylanthranilic acid derivatives and intermediates thereof | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-03-23 | — | — | EP | claimed |
| JP-1246249-A | — | — | None | — | — | JP | disclosed |
| CN-117899063-A | Use of avenanthramides for the production of a product for the prevention and/or treatment of diseases associated with muscular atrophy | 北京工商大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | OCCURX PTY LTD (AU) | 2023-08-31 | — | — | US | disclosed |
| US-4070484-A | Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same | KISSEI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-24 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
| US-3940422-A | ANTIALLERGEN | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (JA) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | TRPM2 2644/4885LTB4R 1900/4885TRPA1 1639/4885 |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | NFATC1, GABRA5, GABRA6 | TRPM2 839/4885LTB4R 665/4885TRPA1 353/4885 |
| US-20230270703-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | ALDH1A2, RBP4, RARB | TRPM2 2891/4885LTB4R 412/4885TRPA1 3144/4885 |
| US-20110112187-A1 | Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions | BDNF, INA, SMN1; SMN2 | TRPM2 842/4885LTB4R 291/4885TRPA1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.